Jaguar Health (JAGX) Financials: History & Chart

Jaguar Health, Inc.(JAGX)

Biotechnology · San Francisco, CA

$5.62+0.89 (+18.82%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

San Francisco, CA

47 employees

jaguar.health

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lisa A. Conte

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	27.82M	1.23M	20.27M	3.23M	3.08M	2.98M	2.21M	3.51M	3.11M
Cost of Goods Sold	4.92M	1.03M	1.16M	2.20M	532K	527K	515K	557K	541K
Gross Profit	22.89M	194K	19.11M	1.03M	2.55M	2.45M	1.70M	2.95M	2.57M
Gross Profit Margin	82.3%	15.8%	94.3%	32.0%	82.7%	82.3%	76.7%	84.1%	82.6%
Total Operating Expenses	47.99M	7.79M	8.93M	21.48M	9.79M	10.46M	11.12M	11.11M	9.83M
Research & Development	25.23M	3.34M	3.93M	14.31M	3.66M	3.27M	3.73M	4.53M	4.04M
Selling, General & Administrative	20.90M	4.46M	5.00M	5.31M	6.13M	7.19M	7.39M	6.58M	5.79M
Operating Income (EBIT)	-25.09M	-7.60M	10.18M	-20.44M	-7.24M	-8.01M	-9.42M	-8.16M	-7.26M
Operating Margin	-90.2%	-620.2%	50.2%	-631.9%	-234.8%	-268.8%	-425.5%	-232.5%	-233.7%
Income Before Tax (EBT)	-36.92M	-12.80M	8.72M	-23.19M	-9.65M	-10.56M	-10.60M	-10.23M	-10.02M
Interest Income	N/A	N/A	N/A	N/A	N/A	15K	56K	110K	162K
Interest Expense	866K	161K	699K	N/A	6K	N/A	N/A	N/A	N/A
Other Income/Expense	-11.82M	-5.21M	-1.46M	-2.75M	-2.41M	-2.55M	-1.18M	-2.08M	-2.76M
Net Income	-36.65M	-12.68M	8.60M	-23.06M	-9.50M	-10.41M	-10.46M	-9.92M	-9.85M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-131.8%	-1035.3%	42.4%	-712.9%	-308.2%	-349.3%	-472.6%	-282.7%	-317.1%
EBITDA	-23.05M	-7.17M	10.70M	-19.90M	-6.68M	-7.45M	-8.88M	-7.56M	-6.67M
EBITDA Margin	-82.9%	-585.4%	52.8%	-615.1%	-216.7%	-250.1%	-400.9%	-215.6%	-214.5%
Depreciation & Amortization	2.05M	426K	520K	543K	557K	556K	546K	593K	596K
EPS Basic	-5482.20	-235.50	-204.00	-1746.00	-3296.70	-5384.10	-8766.60	-9855.45	-13802.70
EPS Diluted	-5482.20	-235.50	-204.00	-1746.00	-3296.70	-5384.10	-8766.60	-9855.45	-13802.70
Weighted Average Basic Shares	54K	54K	34K	13K	3K	2K	1K	1K	714
Weighted Average Diluted Shares	54K	54K	34K	13K	3K	2K	1K	1K	714

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	11.51M	11.69M	9.76M	11.96M	4.33M	9.38M	5.78M	4.42M
Cost of Goods Sold	3.77M	1.96M	2.04M	2.02M	2.33M	3.28M	3.82M	2.77M
Gross Profit	7.74M	9.73M	7.72M	9.94M	2.00M	6.11M	1.96M	1.65M
Gross Profit Margin	67.2%	83.3%	79.1%	83.1%	46.2%	65.1%	33.9%	37.4%
Total Operating Expenses	52.84M	40.56M	42.02M	44.35M	42.71M	32.75M	30.91M	27.26M
Research & Development	24.97M	16.54M	18.60M	17.65M	15.08M	6.41M	5.82M	5.15M
Selling, General & Administrative	26.02M	24.02M	23.05M	26.70M	26.00M	21.00M	20.44M	22.11M
Operating Income (EBIT)	-45.11M	-30.83M	-34.29M	-34.41M	-40.71M	-26.65M	-28.95M	-30.82M
Operating Margin	-391.9%	-263.8%	-351.3%	-287.8%	-939.1%	-283.9%	-501.3%	-698.0%
Income Before Tax (EBT)	-54.00M	-39.25M	-41.90M	-48.40M	-52.60M	-33.81M	-38.53M	-32.15M
Interest Income	N/A	N/A	N/A	N/A	N/A	2.79M	N/A	N/A
Interest Expense	-67K	231K	6.38M	12.72M	8.42M	2.79M	5.73M	2.63M
Other Income/Expense	-8.89M	-8.42M	-7.61M	-13.98M	-11.89M	-7.16M	-9.58M	-1.32M
Net Income	-53.43M	-38.49M	-41.30M	-47.45M	-52.59M	-33.81M	-38.54M	-32.15M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	10K	0.00
Net Profit Margin	-464.2%	-329.3%	-423.1%	-396.9%	-1213.3%	-360.2%	-667.3%	-727.9%
EBITDA	-42.91M	-28.47M	-33.13M	-32.12M	-38.90M	-24.37M	-27.02M	-29.08M
EBITDA Margin	-372.7%	-243.6%	-339.4%	-268.7%	-897.2%	-259.6%	-467.9%	-658.4%
Depreciation & Amortization	2.20M	2.36M	1.16M	2.29M	1.81M	2.28M	1.93M	1.75M
EPS Basic	-12059.25	-68611.05	-1409880.00	-28492920.00	-69476385.00	-177212295.00	-1596051840.00	-27158254770.00
EPS Diluted	-12059.25	-68611.05	-1409880.00	-28492920.00	-69476385.00	-177212295.00	-1596051840.00	-27158254770.00
Weighted Average Basic Shares	4K	561	29	2	1	0	0	0
Weighted Average Diluted Shares	4K	561	29	2	1	0	0	0

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.